Positive ARTISTRY-2 Trial Results for BIC LEN H...

By HEOR Staff Writer

December 17, 2025

BIC/LEN HIV Regimen Delivers Non-Inferior Results in ARTISTRY-2 Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial, demonstrating that ...

HIV Therapy Advancements: Promising Results from Bictegravir/Lenacapavir Comb...

Barriers to African Pharmaceutical Growth: Navigating Regulatory and Procurem...

Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk ...

ViiV Healthcare Licensing: Expanding Access to Long-Acting HIV Treatment in L...

ARVs Water Impact: Examining the Environmental Consequences of Antiretroviral...

Lenacapavir HIV Prevention: Gilead’s Strategic Agreement to Enhance Acc...

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Pr...

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

Cost-Effective HIV PrEP: CAB-LA Transforms Prevention

Cost-Effective Interventions for HIV, Malaria, Syphilis, and TB in 128 Countries

HIV Colorectal Cancer Survival

CKD Prevalence in HIV Patients on TDF: A Global Perspective